


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application No.: 09/555,949

Filed: June 6, 2000

1<sup>st</sup> Inventor: T. ISHIKAWA

For: Phosphonocephem Derivatives, Process for the Preparation of the Same, and Use Thereof

Atty. Dkt. No. 2499 USOP

Art Unit: 1624

Examiner: M. Berch


Allowed:

Batch:

Paper No.: 9

#13

Supplemental Information Disclosure Statement



Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached form PTO-1449 under §1.97(d).

Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account number 500799 for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a Supplemental Information Disclosure Statement.

I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: January 22, 2002

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Mark Chao, Ph.D., Reg. No. 37,293  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
Suite 500, 475 Half Day Road  
Lincolnshire, IL 60069 USA

01/28/2002 CCHRUI 00000082 500799 09555949  
01 FC:126 180.00 CH